70 related articles for article (PubMed ID: 25993868)
1. [Gastroesophageal reflux disease in patients receiving chemotherapy: clinical, endoscopic, morphological and immunohistochemical features].
Gricenko TA; Davydkin IL; Osadchuk AM; Kostalanova JV
Eksp Klin Gastroenterol; 2015; (2):17-23. PubMed ID: 25993868
[TBL] [Abstract][Full Text] [Related]
2. [CLINICAL AND ENDOSCOPIC, MORPHOLOGIC AND IMMUNOHISTOCHEMICAL FEATURES OF GASTRIC ULCER IN H. PYLORI-INFECTED INDIVIDUALS RECEIVING CYTOTOXIC THERAPY].
Sazonova OV; Davydkin IL; Osadchuk AM; Gritsenko TA
Eksp Klin Gastroenterol; 2016; (2):18-24. PubMed ID: 27301112
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease.
Isomoto H; Saenko VA; Kanazawa Y; Nishi Y; Ohtsuru A; Inoue K; Akazawa Y; Takeshima F; Omagari K; Miyazaki M; Mizuta Y; Murata I; Yamashita S; Kohno S
Am J Gastroenterol; 2004 Apr; 99(4):589-97. PubMed ID: 15089887
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease.
Yoshida N; Uchiyama K; Kuroda M; Sakuma K; Kokura S; Ichikawa H; Naito Y; Takemura T; Yoshikawa T; Okanoue T
Scand J Gastroenterol; 2004 Sep; 39(9):816-22. PubMed ID: 15513378
[TBL] [Abstract][Full Text] [Related]
5. Non-cardiac chest pain: the long-term natural history and comparison with gastroesophageal reflux disease.
Williams JF; Sontag SJ; Schnell T; Leya J
Am J Gastroenterol; 2009 Sep; 104(9):2145-52. PubMed ID: 19513020
[TBL] [Abstract][Full Text] [Related]
6. Acid and bile reflux in erosive reflux disease, non-erosive reflux disease and Barrett's esophagus.
Hak NG; Mostafa M; Salah T; El-Hemaly M; Haleem M; Abd El-Raouf A; Hamdy E
Hepatogastroenterology; 2008; 55(82-83):442-7. PubMed ID: 18613384
[TBL] [Abstract][Full Text] [Related]
7. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants.
Mäntynen T; Färkkilä M; Kunnamo I; Mecklin JP; Juhola M; Voutilainen M
Am J Gastroenterol; 2002 Oct; 97(10):2524-9. PubMed ID: 12385433
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in gastroesophageal reflux disease and Barrett's esophagus: ANNO 2012.
Tytgat GN
J Dig Dis; 2012 Jun; 13(6):291-5. PubMed ID: 22624551
[TBL] [Abstract][Full Text] [Related]
9. Gastroesophageal reflux disease does not lead to changes in the secretory leukocyte protease inhibitor expression in esophageal mucosa.
Wex T; Mönkemüller K; Kuester D; Weise S; Kropf S; Fry LC; Stahr A; Völkel S; Roessner A; Malfertheiner P
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):150-8. PubMed ID: 19212204
[TBL] [Abstract][Full Text] [Related]
10. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
Watson TJ; Peters JH
Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
[TBL] [Abstract][Full Text] [Related]
11. Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux.
Nasr AO; Dillon MF; Conlon S; Downey P; Chen G; Ireland A; Leen E; Bouchier-Hayes D; Walsh TN
Surgery; 2012 Mar; 151(3):382-90. PubMed ID: 22019500
[TBL] [Abstract][Full Text] [Related]
12. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease.
Kandulski A; Wex T; Mönkemüller K; Kuester D; Fry LC; Roessner A; Malfertheiner P
Am J Gastroenterol; 2010 Sep; 105(9):1934-43. PubMed ID: 20588261
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database.
Dickman R; Mattek N; Holub J; Peters D; Fass R
Am J Gastroenterol; 2007 Jun; 102(6):1173-9. PubMed ID: 17378910
[TBL] [Abstract][Full Text] [Related]
14. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
Pace F; Pace M
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
[TBL] [Abstract][Full Text] [Related]
15. Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
Mine S; Iida T; Tabata T; Okada Y; Tanaka Y
J Gastroenterol Hepatol; 2008 Feb; 23(2):303-9. PubMed ID: 17725600
[TBL] [Abstract][Full Text] [Related]
16. [The impact of proton pump inhibitors on esophageal acid exposure in gastroesophageal reflux disease].
Liang XY; Chen WN; Lan L; Wang Q; Lü YW; Lan Y
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):513-5. PubMed ID: 22943821
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
18. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
[TBL] [Abstract][Full Text] [Related]
19. Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure.
Noar MD; Lotfi-Emran S
Gastrointest Endosc; 2007 Mar; 65(3):367-72. PubMed ID: 17321232
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
